Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Rating of “Hold” from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given an average recommendation of “Hold” by the fourteen ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $75.10.

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research note on Monday, October 27th. The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective on the stock in a report on Tuesday, October 14th. Zacks Research cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Friday, December 19th.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $68.87 on Monday. Halozyme Therapeutics has a one year low of $47.50 and a one year high of $79.50. The stock has a market cap of $8.10 billion, a PE ratio of 14.50, a P/E/G ratio of 0.37 and a beta of 0.95. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The stock has a 50 day moving average price of $67.34 and a 200 day moving average price of $65.57.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The company had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. During the same period in the prior year, the business earned $1.27 EPS. The firm’s quarterly revenue was up 22.1% on a year-over-year basis. Equities research analysts expect that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, COO Cortney Caudill sold 4,263 shares of Halozyme Therapeutics stock in a transaction dated Saturday, November 1st. The shares were sold at an average price of $65.19, for a total transaction of $277,904.97. Following the completion of the sale, the chief operating officer directly owned 12,737 shares in the company, valued at $830,325.03. This trade represents a 25.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $68.48, for a total transaction of $136,960.00. Following the completion of the sale, the director directly owned 42,952 shares in the company, valued at $2,941,352.96. This trade represents a 4.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 85,661 shares of company stock valued at $6,036,837 over the last 90 days. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HALO. Root Financial Partners LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at $25,000. Larson Financial Group LLC grew its position in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares in the last quarter. Richardson Financial Services Inc. increased its stake in Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares during the period. Clearstead Advisors LLC lifted its position in shares of Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $32,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.